Dr. S. Vincent Rajkumar (Mayo Clinic, Rochester, MN) discusses which five trials he found to be most significant at ASCO 2019:


A phase III randomized, open-label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). In this trial, isatuximab shows to have significantly improved response rates as well as prolonged progression-free survival.

Abstract No: 8004 Clinical trial information: NCT02990338 Citation: J Clin Oncol 37, 2019 (suppl; abstr 8004)

Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. The risk stratification model for SMM incorporates revised cutoffs for previously used parameters (20/2/20) that can be universally applied. Additional analysis is being conducted to develop models that utilize common cytogenetic abnormalities, as well as those without FLC given lack of availability of all tests across the world. 

Abstract No: 8000 Citation: J Clin Oncol 37, 2019 (suppl; abstr 8000)

E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. In this trial, lenalidomide found that early therapy with lenalidomide prevented end organ damage and had no adverse impact on the quality of life. 
 

Abstract No: 8001 Clinical trial information: NCT01169337 Citation: J Clin Oncol 37, 2019 (suppl; abstr 8001)

First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). A trial of the new drug category CC220, a compound made by Celgene, shows significant activity in relapsed/refractory patients. 
 

Abstract No: 8006 Clinical trial information: NCT02773030 Citation: J Clin Oncol 37, 2019 (suppl; abstr 8006)

CASSIOPEIA part 1, a phase III randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM). The trial found that the addition of daratumumab improved response rates and progression-free survival and an improved trend for overall survival. 

Abstract No: 8003  Clinical trial information: NCT02541383  Citation: J Clin Oncol 37, 2019 (suppl; abstr 8003)
 


ABOUT S. VINCENT RAJKUMAR, MD

S. Vincent Rajkumar, M.D., is a Faculty hematologist/oncologist at the Mayo Clinic in Rochester, MN. He conducts research in multiple myeloma and related disorders. He has served as the principal investigator for pivotal clinical trials for the treatment of myeloma. Visit Dr. Rajkumar’s full biography.

 

Previous Post
A phase III study comparing isatuximab, pomalidomide, and low-dose dexamethasone vs pom and low-dose dex in pts with relapsed/refractory multiple myeloma
Next Post
First clinical study of iberdomide, a CELMoD, in pts with relapsed/refractory multiple myeloma

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt out, click for more information.